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epigenetic components in cancer development. In certain cancers,
altered expression of DNA methyltransferase (DNMT) family mem-
bers could potentially cause this DNA methylation re-patterning.
Speciﬁcally, DNMT3B has over thirty different isoforms with varied
expression in tissues (Ostler et al. 2007). Recent studies have
shown that DNMT3B is responsible for gene body methylation by
recognizing the H3K36me3 modiﬁcation found in gene bodies, espe-
cially gene body remethylation after treatment with a DNAmethyla-
tion inhibitor (5-Aza-CdR) (Baubec et al. 2015; Yang et al. 2014). The
methylated gene bodies showedpositive correlationswith gene expres-
sion and, additionally, hypomethylation of gene bodies could lead to
down regulation of gene expression (Yang et al. 2014). Non-small cell
lung cancer (NSCLC) is one such disease which has overexpression of
DNMT3B, including a speciﬁc subfamily which lacks an N-terminal
domain (ΔDNMT3B) (Wang et al. 2006). In this issue of EBioMedicine
the work presented by Ma et al. (Ma et al. 2015), provides exciting
developments for NSCLC with ﬁndings connecting the aberrant DNA
methylation patterns during tumorigenesis with the predominantly
expressed DNMT3B isoform: ΔDNMT3B4-del, a truncated DNMT3B iso-
form lacking exons 21 and/or 22 which contain the catalytic domain.
DNMTs responsible for DNA methylation establishment include:
DNMT1, DNMT3A and DNMT3B, as well as DNMT3L (DNAmethyltrans-
ferase 3-like). DNMT3A and B are the de novo methyltransferases
responsible for developing new methylation patterns in the genome
as well as maintenance of stable gene silencing related to key biological
processes. Generally, tumorigenesis involves DNA hypermethylation at
CpG islands (CGI) as well as global DNA hypomethylation (Jones
2012). Although there are many studies that focus on a speciﬁc DNMT
and their role during development and cancer, there is still a knowledge
gap with respect to how the plethora of DNMT isoforms contributes to
DNA methylation alterations.
The work by Ma et al. builds on the foundation that primary
NSCLC tumors aberrantly express ΔDNMT3B from earlier studies
with ΔDNMT3B4 being the most prevalent isoform (Wang et al.
2007). Additionally, ΔDNMT3B4 can have a truncated methyltrans-
ferase domain (ΔDNMT3B4-del) that was shown to facilitate DNA
methylation changes in transgenicmice similar to early initiating events
in tumorigenesis. Interestingly, approximately half of the NSCLC tumorsDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.09.002.
⁎ Corresponding author.
E-mail address: gliang@usc.edu (G. Liang).
http://dx.doi.org/10.1016/j.ebiom.2015.09.020
2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article underexpressed DNMT3B-del variants. Aberrant expression of ΔDNMT3B4-del
could not fully explain the development of NSCLC however; this ﬁnding
highlights how DNMT3B isoforms could be potential targets for cancer
therapy.
The observed DNA methylation changes could be initiation events
for tumorigenesis in NSCLC and is interesting because this shows the
impact of one aberrantly expressed DNMT isoform in normal tissue.
The transgenic mouse experiments by Ma et al., where ΔDNMT3B4-del
was exogenously introduced to the genome, resulted in lung speciﬁc
global hypomethylation, a hallmark of aberrant DNA methylation
found during early tumorigenesis (Jones and Baylin 2007). The global
hypomethylation could be caused by ΔDNMT3B4-del interacting or
preventing interactions between other DNMT family members or the
loss of its catalytic domain but requires further in depth functional stud-
ies. The functions of ΔDNMT3B4-del is not fully understood, nor are the
effects of the induced global hypomethylation during tumorigenesis
potentially due to its truncated catalytic domain. Nevertheless, the
authors used in vitro model systems to study ΔDNMT3B4-del, ﬁnding
cells became arrested in the G2/M phase, had increased abnormal
DNA content and elevated levels of DNA damage response genes
consistent with lung tumorigenesis. Furthermore, the authors show
that, although ΔDNMT3B4-del on its own is incapable of inducing
tumorigenesis, in combinationwith carcinogen exposure the transgenic
animals develop adenocarcinoma formations. Summarizing these
results, it suggests the ΔDNMT3B4-del plays a critical role in promoting
genomic instability providing the groundwork for tumor initiation and
formation in NSCLC.
These intriguing ﬁndings raise multiple new questions. Could
other DNMT3B isoform family members provide the ﬁrst necessary
methylome changes resulting in tumor initiation?HowdoDNMT family
members interact with each other when one constituent is over pro-
duced?Will targeting speciﬁc DNMTs be necessary in cancer treatment
and prevention? Answering these questionswill be pivotal in providing
functional characteristics about DNAmethyltransferases and their roles
in tumorigenesis. Furthermore it will provide a possible new foundation
of how speciﬁc genes changing the epigenome can inﬂuencemore dras-
tic changes leading to tumor evolution.
One problem with targeting DNA methylation is the availability of
speciﬁc inhibitors for DNMTs. Although 5-azacytidine (5-Aza-CR) and
5-aza-2′-deoxycitidine (5-Aza-CdR) are FDA approved for treatment
of myeloid malignances, they lead to the trapping and degradation of
DNMTs resulting in passive DNA methylation loss after replication
(Ghoshal et al. 2005; Kuo et al. 2007). The best type of therapy wouldthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1273C.E. Duymich, G. Liang / EBioMedicine 2 (2015) 1272–1273be one that targets speciﬁc proteins like ΔDNMT3B4-del to restore
normal expression of the DNMT family instead of targeting all consti-
tutes and possibly causing off target effects. The identiﬁcation of drugs
that could speciﬁcally target one DNA methyltransferase will be an in-
terestingﬁeld of researchwith a potential therapeutic impact on various
diseases.
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